Beam Therapeutics annual total debt
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Total Debt Growth & History (BEAM)
Beam Therapeutics's total debt was $154.1M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $154.1M | −$7.3M | −4.52% |
| 2024 | 2024-12-31 | $161.4M | −$11.3M | −6.52% |
| 2023 | 2023-12-31 | $172.7M | −$9.3M | −5.12% |
| 2022 | 2022-12-31 | $182.0M | $34.4M | +23.28% |
| 2021 | 2021-12-31 | $147.6M | $40.0M | +37.16% |
| 2020 | 2020-12-31 | $107.6M | $76.4M | +244.59% |
| 2019 | 2019-12-31 | $31.2M | — | — |
Beam Therapeutics quarterly total debt
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $247.4M | $92.6M | +59.79% |
| Q1 2026 | 2026-03-31 | $250.8M | $92.7M | +58.62% |
| Q4 2025 | 2025-12-31 | $154.1M | −$7.3M | −4.52% |
| Q3 2025 | 2025-09-30 | $151.4M | −$10.6M | −6.57% |
| Q2 2025 | 2025-06-30 | $154.8M | −$10.4M | −6.31% |
| Q1 2025 | 2025-03-31 | $158.1M | −$10.0M | −5.94% |
| Q4 2024 | 2024-12-31 | $161.4M | −$11.3M | −6.52% |
| Q3 2024 | 2024-09-30 | $162.1M | −$11.9M | −6.85% |
| Q2 2024 | 2024-06-30 | $165.2M | −$11.9M | −6.71% |
| Q1 2024 | 2024-03-31 | $168.1M | −$10.7M | −6.00% |
| Q4 2023 | 2023-12-31 | $172.7M | −$9.3M | −5.12% |
| Q3 2023 | 2023-09-30 | $174.0M | −$4.5M | −2.53% |
| Q2 2023 | 2023-06-30 | $177.1M | −$543,000 | −0.31% |
| Q1 2023 | 2023-03-31 | $178.9M | $28.7M | +19.13% |
| Q4 2022 | 2022-12-31 | $182.0M | $34.4M | +23.28% |
| Q3 2022 | 2022-09-30 | $178.5M | $33.1M | +22.73% |
| Q2 2022 | 2022-06-30 | $177.7M | $35.0M | +24.55% |
| Q1 2022 | 2022-03-31 | $150.1M | $13.5M | +9.91% |
| Q4 2021 | 2021-12-31 | $147.6M | $40.0M | +37.16% |
| Q3 2021 | 2021-09-30 | $145.4M | $111.1M | +323.64% |
| Q2 2021 | 2021-06-30 | $142.6M | $106.5M | +294.16% |
| Q1 2021 | 2021-03-31 | $136.6M | $100.8M | +282.07% |
| Q4 2020 | 2020-12-31 | $107.6M | $76.4M | +244.59% |
| Q3 2020 | 2020-09-30 | $34.3M | — | — |
| Q2 2020 | 2020-06-30 | $36.2M | — | — |
| Q1 2020 | 2020-03-31 | $35.8M | — | — |
| Q4 2019 | 2019-12-31 | $31.2M | — | — |
Beam Therapeutics total debt trends
Over the last five fiscal years, Beam Therapeutics's total debt increased from $107.6M to $154.1M, a change of $46.5M. The latest reported quarter, Q2 2026, shows $247.4M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...